231 related articles for article (PubMed ID: 23845471)
1. MUC1 is expressed at high frequency in early-stage basal-like triple-negative breast cancer.
Siroy A; Abdul-Karim FW; Miedler J; Fong N; Fu P; Gilmore H; Baar J
Hum Pathol; 2013 Oct; 44(10):2159-66. PubMed ID: 23845471
[TBL] [Abstract][Full Text] [Related]
2. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype.
Cheang MC; Voduc D; Bajdik C; Leung S; McKinney S; Chia SK; Perou CM; Nielsen TO
Clin Cancer Res; 2008 Mar; 14(5):1368-76. PubMed ID: 18316557
[TBL] [Abstract][Full Text] [Related]
3. Triple-negative breast cancer: current state of the art.
Rastelli F; Biancanelli S; Falzetta A; Martignetti A; Casi C; Bascioni R; Giustini L; Crispino S
Tumori; 2010; 96(6):875-88. PubMed ID: 21388048
[TBL] [Abstract][Full Text] [Related]
4. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
Tsutsumi Y
Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of the cancer stem cell related markers ALDH1 and EZH2 in triple negative and basal-like breast cancers.
De Brot M; Rocha RM; Soares FA; Gobbi H
Pathology; 2012 Jun; 44(4):303-12. PubMed ID: 22544210
[TBL] [Abstract][Full Text] [Related]
6. Implications of different CA 15-3 levels according to breast cancer subtype at initial diagnosis of recurrent or metastatic breast cancer.
Park S; Ahn HK; Park LC; Hwang DW; Ji JH; Maeng CH; Cho SH; Lee JY; Park KT; Ahn JS; Park YH; Im YH
Oncology; 2012; 82(3):180-7. PubMed ID: 22433564
[TBL] [Abstract][Full Text] [Related]
7. Feline mammary basal-like adenocarcinomas: a potential model for human triple-negative breast cancer (TNBC) with basal-like subtype.
Wiese DA; Thaiwong T; Yuzbasiyan-Gurkan V; Kiupel M
BMC Cancer; 2013 Sep; 13():403. PubMed ID: 24004841
[TBL] [Abstract][Full Text] [Related]
8. Dysregulation of the epigenome in triple-negative breast cancers: basal-like and claudin-low breast cancers express aberrant DNA hypermethylation.
Roll JD; Rivenbark AG; Sandhu R; Parker JS; Jones WD; Carey LA; Livasy CA; Coleman WB
Exp Mol Pathol; 2013 Dec; 95(3):276-87. PubMed ID: 24045095
[TBL] [Abstract][Full Text] [Related]
9. Variations in tumor marker levels in metastatic breast cancer patients according to tumor subtypes.
Kos T; Aksoy S; Sendur MA; Arik Z; Civelek B; Kandemir N; Ozdemir NY; Zengin N; Altundag K
J BUON; 2013; 18(3):608-13. PubMed ID: 24065471
[TBL] [Abstract][Full Text] [Related]
10. Lymphatic and blood vessels in basal and triple-negative breast cancers: characteristics and prognostic significance.
Mohammed RA; Ellis IO; Mahmmod AM; Hawkes EC; Green AR; Rakha EA; Martin SG
Mod Pathol; 2011 Jun; 24(6):774-85. PubMed ID: 21378756
[TBL] [Abstract][Full Text] [Related]
11. The role of tumor hypoxia in MUC1-positive breast carcinomas.
Zanetti JS; Soave DF; Oliveira-Costa JP; da Silveira GG; Ramalho LN; Garcia SB; Zucoloto S; Ribeiro-Silva A
Virchows Arch; 2011 Oct; 459(4):367-75. PubMed ID: 21892751
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society.
Iwase H; Kurebayashi J; Tsuda H; Ohta T; Kurosumi M; Miyamoto K; Yamamoto Y; Iwase T
Breast Cancer; 2010 Apr; 17(2):118-24. PubMed ID: 19466512
[TBL] [Abstract][Full Text] [Related]
13. Association between mammographic density and basal-like and luminal A breast cancer subtypes.
Razzaghi H; Troester MA; Gierach GL; Olshan AF; Yankaskas BC; Millikan RC
Breast Cancer Res; 2013; 15(5):R76. PubMed ID: 24008056
[TBL] [Abstract][Full Text] [Related]
14. The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome in 'pure' ductal carcinoma in situ of the breast.
de Roos MA; van der Vegt B; Peterse JL; Patriarca C; de Vries J; de Bock GH; Wesseling J
Histopathology; 2007 Aug; 51(2):227-38. PubMed ID: 17650217
[TBL] [Abstract][Full Text] [Related]
15. Triple-negative/basal-like breast cancer: review.
Rakha EA; Ellis IO
Pathology; 2009 Jan; 41(1):40-7. PubMed ID: 19089739
[TBL] [Abstract][Full Text] [Related]
16. Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers.
Liu H; Fan Q; Zhang Z; Li X; Yu H; Meng F
Hum Pathol; 2008 Feb; 39(2):167-74. PubMed ID: 18045647
[TBL] [Abstract][Full Text] [Related]
17. Altered intracellular region of MUC1 and disrupted correlation of polarity-related molecules in breast cancer subtypes.
Iizuka M; Nakanishi Y; Fuchinoue F; Maeda T; Murakami E; Obana Y; Enomoto K; Tani M; Sakurai K; Amano S; Masuda S
Cancer Sci; 2015 Mar; 106(3):307-14. PubMed ID: 25556893
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological characteristics of triple negative breast cancer at a tertiary care hospital in India.
Dogra A; Doval DC; Sardana M; Chedi SK; Mehta A
Asian Pac J Cancer Prev; 2014; 15(24):10577-83. PubMed ID: 25605142
[TBL] [Abstract][Full Text] [Related]
19. Fragile histidine triad protein, WW domain-containing oxidoreductase protein Wwox, and activator protein 2gamma expression levels correlate with basal phenotype in breast cancer.
Guler G; Huebner K; Himmetoglu C; Jimenez RE; Costinean S; Volinia S; Pilarski RT; Hayran M; Shapiro CL
Cancer; 2009 Feb; 115(4):899-908. PubMed ID: 19130459
[TBL] [Abstract][Full Text] [Related]
20. CA 15-3 (Mucin-1) and physiological characteristics of breast cancer from Lahore, Pakistan.
Begum M; Karim S; Malik A; Khurshid R; Asif M; Salim A; Nagra SA; Zaheer A; Iqbal Z; Abuzenadah AM; Alqahtani MH; Rasool M
Asian Pac J Cancer Prev; 2012; 13(10):5257-61. PubMed ID: 23244146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
